The treatment landscape for men with advanced prostate cancer keeps on shifting and expanding. As new therapy options continue to emerge, it is important to understand which treatment options are currently available and how they work in fighting the disease. To highlight a few of the new options, we have Dr. Natasha Kyprianou, an award-winning prostate cancer investigator, joining us on the podcast today to help you get up to speed. Stay tuned for more! Dr. Natasha Kyprianou completed her fellowship in molecular oncology at Johns Hopkins University and in molecular biology at the Imperial Cancer Research Fund in London, UK. She is a professor in the Department of Urology in Oncological Sciences at Mount Sinai Medical Center in New York City and a member of the National Cancer Institute-designated Tisch Cancer Institute. She has also been active nationally and internationally in several leadership positions, including being a board member of the International Prostate Health Council, member of the American Urologic Association Education Council, and honorary board member of the EAU Council, and has served as President of the Society for Basic Urologic Research. It is also worth noting that she was also the Chair of the Department of Defence Congressional Directed Program for Prostate Cancer Research, and was the first female to be elected to this position. Her research focuses on the molecular mechanisms underlying prostate cancer progression to metastasis and apoptosis-driven molecular therapeutics that are targeting urologic tumors. During her career, she has received numerous awards, including being the first female to be awarded by the American Urologic Association for her contribution to urology research. Be sure to listen in to find out what Dr. Kyprianou has to say about the new treatment options that are currently available for advanced prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show highlights: Dr. Kyprianou explains what motivated her to follow the path she has taken to get to where she is today. More than thirty-thousand men will die of prostate cancer in 2021. The survival rates for prostate cancer drop dramatically once cancer has metastasized to distant sites. Dr. Kyprianou explains what it means for a man to undergo Androgen Deprivation Therapy (ADT). Dr. Kyprianou discusses the novel agents developed in recent years for the treatment of advanced prostate cancer. Dr. Kyprianou talks about the role of the androgen receptor in driving advanced prostate cancer. Dr. Kyprianou explains how the new novel medication, Enzalutamide, also known as Xtandi, works in helping men with advanced prostate cancer. Dr. Kyprianou explains from a research perspective how a treatment like Enzalutamide gets discovered and then ultimately brought to the point where it becomes available to the consumer. Dr. Kyprianou talks about some of the more commonly reported side-effects of Enzalutamide. How the novel agent, Abiraterone, or Azteca, works in helping men with advanced prostate cancer. Dr. Kyprianou explains why men need to keep getting their ADT injections with the new therapy once their prostate cancer has become resistant to the standard hormonal therapy. Dr. Kyprianou discusses what the next ten years hold for the advancement of treatment options for men with advanced prostate cancer. Links and resources: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link here, on our podcast website) Join our Facebook group Follow Dr. Pohlman on Twitter and Instagram Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content. You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related